Latest Insider Transactions at Sab Biotherapeutics, Inc. (SABS)
This section provides a real-time view of insider transactions for Sab Biotherapeutics, Inc. (SABS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SAB Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SAB Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2021
|
Russell P Beyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
154
+50.0%
|
$1,540
$10.08 P/Share
|
|
Jan 14
2021
|
Big Cypress Holdings LLC CEO and CFO |
BUY
Open market or private purchase
|
Direct |
417,200
+12.04%
|
$4,172,000
$10.0 P/Share
|
|
Jan 14
2021
|
Ilan Katz Director |
BUY
Open market or private purchase
|
Indirect |
417,200
+12.04%
|
$4,172,000
$10.0 P/Share
|
|
Jan 14
2021
|
Samuel J Reich CEO & EXECUTIVE CHAIRMAN |
BUY
Open market or private purchase
|
Indirect |
417,200
+12.04%
|
$4,172,000
$10.0 P/Share
|